Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE MEDICAL DEVICE NEWS IN BRIEF
April 23, 2007
-
ARCHIVE Crestor Effective in Low-Risk Arteriosclerosis Patients: METEOR Study
April 23, 2007
-
ARCHIVE Sawai to Increase Calls to DPC Hospitals
April 23, 2007
-
ARCHIVE NEW PRODUCT/Follistim Launched for New Indication: Nippon Organon
April 23, 2007
-
ARCHIVE GENERIC NEWS IN BRIEF
April 23, 2007
-
ARCHIVE Shionogi to Hire More MRs to Promote Crestor, Irbesartan
April 23, 2007
-
ARCHIVE Medical Spending Should Be Increased: JMA President
April 23, 2007
-
ARCHIVE Asahi Kasei to Focus on 3 Fields
April 23, 2007
-
ARCHIVE Strict Control of cholesterol Required in Hyperlipidemia Patients with Diabetes
April 23, 2007
-
ARCHIVE Explosion at Shin-Etsu Chemical Affects Supply of Cellulose Derivatives
April 23, 2007
-
ARCHIVE Early Treatment of Hepatitis C Needed to Prevent Liver Cancer
April 23, 2007
-
ARCHIVE 90% of Doctors Predict Increases in Cerebro-, Cardiovascular Diseases: Prof. Teramoto
April 16, 2007
-
ARCHIVE Ordinary Single-Dose Tox Studies Sufficient to Initiate MD Studies: Symposium
April 16, 2007
-
ARCHIVE Daiichi Sankyo Sets Out To Become a "Global Pharma Innovator"
April 16, 2007
-
ARCHIVE R&D NEWS IN BRIEF
April 16, 2007
-
ARCHIVE Mochida to Increase MRs to 750 by FY2009
April 16, 2007
-
ARCHIVE TOPICS/Abilify Receives PSJ Award: Otsuka
April 16, 2007
-
ARCHIVE Industry's Highest Growth Rate Recorded Twice in 2 Years: NBI
April 16, 2007
-
ARCHIVE Use of 9 Reagents for Pancreatic Islet Transplantations Restricted
April 16, 2007
-
ARCHIVE Janssen's Sales Drop 11.8% Due to NHI Price Cuts
April 16, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…